Mirum Shares Surge More Than 90% in 6 Months: Here's Why

Shares of Mirum Pharmaceuticals, Inc. (MIRM) have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%.The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome worldwide.In March 2024, the FDA approved Livmarli for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahe ...